Vivoryon Therapeutics N.V. to Report Half Year 2023 Financial Results and Operational Progress on September 07, 2023
August 31, 2023 01:00 ET
|
Vivoryon Therapeutics N.V.
Vivoryon Therapeutics N.V. to Report Half Year 2023 Financial Results and Operational Progress on September 07, 2023 Halle (Saale) / Munich, Germany, August 31, 2023 - Vivoryon Therapeutics N.V....
Vivoryon Therapeutics N.V. Extraordinary General Meeting to Confirm New Executive Director Appointments to the Board, Being Held on September 15, 2023
August 04, 2023 17:35 ET
|
Vivoryon Therapeutics N.V.
Vivoryon Therapeutics N.V. Extraordinary General Meeting to Confirm New Executive Director Appointments to the Board, Being Held on September 15, 2023 Halle (Saale) / Munich, Germany, August 4, 2023...
Vivoryon Therapeutics N.V. Announces Proposed Appointment of Dr. Frank Weber as Chief Executive Officer
August 04, 2023 17:30 ET
|
Vivoryon Therapeutics N.V.
Vivoryon Therapeutics N.V. Announces Proposed Appointment of Dr. Frank Weber as Chief Executive Officer Frank Weber, MD, current Chief Medical Officer (CMO), promoted to Chief Executive Officer...
Vivoryon Therapeutics N.V. Shares Clinical Development Update Highlighting Progress of N3pE-Amyloid-targeting Small Molecule Varoglutamstat in Alzheimer’s Disease
July 16, 2023 03:00 ET
|
Vivoryon Therapeutics N.V.
Vivoryon Therapeutics N.V. Shares Clinical Development Update Highlighting Progress of N3pE-Amyloid-targeting Small Molecule Varoglutamstat in Alzheimer’s Disease Small molecule varoglutamstat,...
Vivoryon Therapeutics N.V. Reports Outcome of 2023 Annual General Meeting
June 21, 2023 12:02 ET
|
Vivoryon Therapeutics N.V.
Vivoryon Therapeutics N.V. Reports Outcome of 2023 Annual General Meeting All proposed resolutions approvedElection of two new Non-Executive Board members Halle (Saale) / Munich, Germany, June...
Vivoryon Therapeutics N.V. Announces CEO Transition Plan
June 15, 2023 11:49 ET
|
Vivoryon Therapeutics N.V.
Vivoryon Therapeutics N.V. Announces CEO Transition Plan Dr. Ulrich Dauer not to extend current term running through 2024 AGMBoard to initiate succession planning Halle (Saale) / Munich,...
Vivoryon Therapeutics N.V. to Participate in Upcoming Conferences
June 01, 2023 01:00 ET
|
Vivoryon Therapeutics N.V.
Vivoryon Therapeutics N.V. to Participate in Upcoming Conferences Halle (Saale) / Munich, Germany, June 1, 2023 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a...
Vivoryon Therapeutics Successfully Completes Private Placement Raising EUR 25 Million
May 26, 2023 01:39 ET
|
Vivoryon Therapeutics N.V.
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, JAPAN, AUSTRALIA, SOUTH AFRICA OR ANY OTHER JURISDICTION...
Vivoryon Therapeutics Launches Capital Increase by Way of an Accelerated Bookbuild Offering
May 25, 2023 11:50 ET
|
Vivoryon Therapeutics N.V.
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, JAPAN, AUSTRALIA, SOUTH AFRICA OR ANY OTHER JURISDICTION...
Vivoryon Therapeutics N.V. Reports Q1 2023 Financial Results and Highlights Operational Progress
May 16, 2023 01:00 ET
|
Vivoryon Therapeutics N.V.
Vivoryon Therapeutics N.V. Reports Q1 2023 Financial Results and Highlights Operational Progress Halle (Saale) / Munich, Germany, May 16, 2023 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY;...